| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
We have examined the antitumor effect of the combined therapy of BCG and immune checkpoint inhibitor in a mouse local bladder cancer model. We could get the result that the combination therapy had a stronger antitumor effect than BCG monotherapy. Although, we analyzed various method to confirm the mechanism of the combination therapy. As a result, I could not find the evidence that the acquired immunocytes such as cytotoxic CD8 + T cells (CTL) was responsibility. The further research is needed to find out the reason for this.
|
